Crystalline forms of therapeutic compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-10618906-B2
Application number	US-201816184760-A
Country	US
Kind code	B2
Filing date	Nov 8, 2018
Priority date	Nov 1, 2013
Publication date	Apr 14, 2020
Grant date	Apr 14, 2020

Abstract

Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.

First claim

What is claimed is:

1. A method of inhibiting aberrant vascular endothelial growth factor (VEGF) signaling comprising administering to a subject in need thereof a therapeutically effective amount of crystalline form B of 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane having an X-ray powder diffraction (XRPD) pattern with peaks at about 7.70, 13.53, 17.27, 18.44, 19.73, 23.10 and 26.07±0.3 degrees two theta or 11.47, 6.54, 5.13, 4.81, 4.50, 3.85 and 3.41±0.3 Å in d-spacing.

2. The method of claim 1 , wherein crystalline Form B further has XRPD peaks at about 9.87, 12.88, 14.40, 15.45, 21.14 and 26.84±0.3 degrees two theta or 8.96, 6.87, 6.14, 5.73, 4.20 and 3.32±0.3 Å in d-spacing.

3. The method of claim 1 , wherein crystalline Form B has the XRPD pattern as shown in FIG. 1 .

4. The method of claim 1 , wherein the crystalline form is administered topically, by injection, to the eye, orally, or by inhalation.

5. The method of claim 1 , wherein the inhibition of aberrant VEGF signaling treats an ocular disease.

6. The method of claim 5 , wherein the ocular disease is retinopathy, age-related macular degeneration, corneal neovascularization, diabetic macular edema, or retinal vein occlusion.

7. The method of claim 1 , wherein the aberrant signaling of VEGF is associated with cancer.

8. The method of claim 1 , wherein the inhibition of VEGF signaling comprises inhibiting abnormal angiogenesis.

9. A method of inhibiting aberrant vascular endothelial growth factor (VEGF) signaling comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
crystalline form B of 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane having an XRPD pattern with peaks at about 7.70, 13.53, 17.27, 18.44, 19.73, 23.10 and 26.07±0.3 degrees two theta or 11.47, 6.54, 5.13, 4.81, 4.50, 3.85 and 3.41±0.3 Å in d-spacing; and
one or more pharmaceutically acceptable excipients.

10. The method of claim 9 , wherein the crystalline form is administered topically, by injection, to the eye, orally, or by inhalation.

11. The method of claim 9 , wherein the inhibition of aberrant VEGF signaling treats an ocular disease.

12. The method of claim 11 , wherein the ocular disease is retinopathy, age-related macular degeneration, corneal neovascularization, diabetic macular edema, or retinal vein occlusion.

13. The method of claim 9 , wherein the aberrant signaling of VEGF is associated with cancer.

14. The method of claim 9 , wherein the inhibition of VEGF signaling comprises inhibiting abnormal angiogenesis.

Assignees

• Kala Pharmaceuticals Inc

Inventors

• Enlow Elizabeth
• Nguyen Minh Ngoc
• Ong Winston Z

Classifications

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61K9/0034

  Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title

• A61K9/146

  with organic macromolecular compounds · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K9/5021

  Organic macromolecular compounds · CPC title